Targeting DCs through IgG immune complexes has been proven to be superior to soluble immune complexes for inducing CD8+ T cell responses and as anti-tumor vaccines by utilizing murine bone marrow-derived DCs (76, 77). Here, CD8A is linked to neoplasm.